Literature DB >> 33057709

Poor preoperative quality of life predicts prolonged hospital stay after VATS lobectomy for lung cancer.

Cecilia Pompili1,2, Finn McLennan Battleday1, Wei Ling Chia1, Nilanjan Chaudhuri2, Emmanuel Kefaloyannis2, Richard Milton2, Kostas Papagiannopoulos2, Peter Tcherveniakov2, Alessandro Brunelli2.   

Abstract

OBJECTIVES: The aim of this study was to assess whether quality of life (QoL) scales are associated with postoperative length of stay (LoS) following video-assisted thoracoscopic surgery (VATS) lobectomy for lung cancer.
METHODS: This is a single-centre retrospective analysis on 250 consecutive patients submitted to VATS lobectomies (233) or segmentectomies (17) over a period of 3 years. QoL was assessed in all patients by the self-administration of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 questionnaire. The individual QoL scales were tested for possible association with LoS along with other objective baseline and surgical parameters using univariable and multivariable analyses.
RESULTS: Thirty-day cardiopulmonary and mortality rates were 22% and 2.4%. The median LoS was 4 days [interquartile range (IQR) 3-7]. Fifty-one (20%) patients remained in hospital longer than 7 days after surgery (upper quartile). General health [global health score (GHS)] (P = 0.019), physical function (P = 0.014) and role functioning (P = 0.016) scales were significantly worse in patients with prolonged stay. They were highly correlated between each other and tested separately in different logistic regression analyses. The best model resulted the one containing GHS (P = 0.032) along with age, low force expiratory volume in 1 s and carbon monoxide lung diffusion capacity and history of cerebrovascular disease. Fifty-nine patients had GHS <58 (lower interquartile value). Thirty-one percent of them experienced prolonged hospital stay (vs 17% of those with higher GHS, P = 0.027).
CONCLUSIONS: Preoperative patient-reported QoL was associated with prolonged postoperative hospital stay. Baseline QoL status should be taken into consideration to implement psychosocial supportive programmes in the context of enhanced recovery after surgery.
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Enhanced recovery after surgery; Lobectomy; Lung cancer surgery; Patient-reported outcomes; Quality of life; Segmentectomy

Year:  2021        PMID: 33057709     DOI: 10.1093/ejcts/ezaa245

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  Effects of Osimertinib Combined With Pulmonary Rehabilitation and Health Care Training on Pulmonary Function, Complications, and Quality of Life in Patients After Radical Resection of Lung Cancer.

Authors:  Haijiang Xu; Ruixia Guo; Yantao Yang
Journal:  Front Public Health       Date:  2022-06-10

2.  Reasons for staying in hospital after video-assisted thoracoscopic surgery lobectomy.

Authors:  Lin Huang; Henrik Kehlet; René Horsleben Petersen
Journal:  BJS Open       Date:  2022-05-02

3.  Clinical Efficacy of Thoracoscopic Surgery with the da Vinci Surgical System versus Video-Assisted Thoracoscopic Surgery for Lung Cancer.

Authors:  Jin-Cai Zhou; Wu-Ping Wang; Shu-Qiang Wu; Jia-Lin Wang; Wen-Hai Li
Journal:  J Oncol       Date:  2022-06-08       Impact factor: 4.501

4.  Physiological Biomarkers Assessed by Low-Tech Exercise Tests Predict Complications and Overall Survival in Patients Undergoing Pneumonectomy Due to Lung Cancer.

Authors:  Tomasz Marjanski; Damian Wnuk; Robert Dziedzic; Marcin Ostrowski; Wioletta Sawicka; Ewa Marjanska; Witold Rzyman
Journal:  Cancers (Basel)       Date:  2021-02-10       Impact factor: 6.639

5.  An explainable machine learning framework for lung cancer hospital length of stay prediction.

Authors:  Belal Alsinglawi; Osama Alshari; Mohammed Alorjani; Omar Mubin; Fady Alnajjar; Mauricio Novoa; Omar Darwish
Journal:  Sci Rep       Date:  2022-01-12       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.